mAbxience and Biosidus Sign CDMO Agreement for the Manufacture of Agalsidase Beta for the Treatment of Fabry Disease

Contributed by: PR Newswire

Tags

mAbxience-Biosidus

More Like This

PR Newswire associated0

mAbxience Appoints Jurgen Van Broeck as New CEO

PR Newswire associated0

Abbott Broadens Access to Cutting-Edge Biosimilars in Key Emerging Markets

Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates

WuXi Biologics Congratulates Amicus Therapeutics on U.S. FDA Approval for New Treatment for Pompe Disease

Pharmanovia Signs Novel Biologic In-Licensing Agreement With Lindis Biotech to Commercialise Catumaxomab for Treatment of Rare Condition, Malignant Ascites

PR Newswire associated0

Cambrex Announces Strategic Agreement with Lilly to Support Biotech Collaborator Manufacturing

GlobeNewswire associated0

Essential Pharma reaches agreement with AGC Biologics for late phase clinical manufacturing of its immunotherapy candidate for the treatment of high-risk neuroblastoma

PR Newswire associated0

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa